

# MiRank: A bioinformatics tool for gene/miRNA ranking and pathway profiling with TCGA–KEGG data sets

Siddharth G. Reddy<sup>1,2</sup>, Weimin Xiao<sup>2</sup>, and Preethi H. Gunaratne<sup>2</sup>

<sup>1</sup>Phillips Exeter Academy, Exeter, New Hampshire 03833, USA

<sup>2</sup>Department of Biology and Biochemistry, University of Houston, Houston, Texas 77204, USA

Project hosting: <http://code.google.com/p/miranktool>

## Abstract

The Cancer Genome Atlas (TCGA) provides researchers with clinicopathological data and genomic characterizations of various carcinomas. These data sets include expression microarrays for genes and microRNAs – short, non-coding strands of RNA that downregulate gene expression through RNA interference – as well as `days_to_death` and `days_to_last_followup` fields for each tumor sample. Our aim is to develop a software tool that screens TCGA data sets for genes/miRNAs with functional involvement in specific cancers. Furthermore, our computational pipeline is intended to produce a set of visualizations, or profiles, that place our screened outputs in a pathway-centric context.

We accomplish our ‘screening’ by ranking genes/miRNAs by the correlation of their expression misregulation with differential patient survival. In other words, if a gene/miRNA is consistently misregulated in patients with poor survival rates and, on the other hand, is expressed more ‘normally’ in patients with longer survival rates, then it is ranked highly; if its misregulation has no such correlation with good/bad survival in patients, then its rank is low. Our pathway profiling pipeline produces several outputs, which allow us to examine the functional roles played by highly ranked genes discovered by our screening.

Running the *OV* (ovarian serous cystadenocarcinoma) data set through our analysis pipeline, we find that several highly ranked pathways and functional groups of genes (VEGF, Jun, Fos, etc.) have already been shown to play some part in the development of epithelial ovarian carcinomas. We also observe that several top-ranking miRNAs target oncogenes in the top two quartiles of our rank-ordered list, implying that our ranking scheme is sound in principle and effectively sorts genes/miRNAs by their functional involvement in cancer.

Our outputs suggest that the dysfunction of the Wnt signaling pathway, which regulates cell-fate specification and progenitor cell differentiation, has a disproportionate impact on the survival of ovarian cancer patients. This work has immediate implications: (1) efficient cancer diagnostics with microarrays for highly ranked genes/miRNAs in Wnt, and (2) novel drug treatments that target Wnt as well as other highly ranked pathways and functional groups of genes. It also motivates the improvement of MiRank to take into consideration the network of interactions between gene products and the optimization of node selection by cancer, a disease that evolves to selectively misregulate certain genes in order to lead a cell through tumorigenesis.

# Contents

<b>1</b>	<b>Introduction</b>	<b>3</b>
<b>2</b>	<b>Methods</b>	<b>4</b>
2.1	Expression Misregulation Metric $X$	4
2.2	MiRank-A	5
2.2.1	Survival Spreads	5
2.2.2	Log-Rank Matrices	6
2.2.3	Rank Spread	7
2.2.4	Expression-Survival Correlation Statistic $T$	8
2.3	MiRank-B	8
2.3.1	Patient Grouping	8
2.3.2	Expression and Correlation Statistics	9
2.3.3	Recombination	10
2.3.4	Expression-Survival Correlation Statistic $M$	11
2.4	MiRank-C	11
2.4.1	Survival Analysis	11
2.4.2	Cox Proportional-Hazards Model	12
2.4.3	Cox Regression	12
2.4.4	Gradient Descent with Modification	13
2.5	Pathway Profiling	14
2.5.1	Consolidated Rank $\alpha$	14
2.5.2	KEGG Pathway Enrichment	14
2.5.3	Clustering	16
2.5.4	Partitioning	16
2.5.5	GO Term Enrichment	17
<b>3</b>	<b>Results</b>	<b>17</b>
3.1	Gene/miRNA Ranking	17
3.2	Prognostic Index Performance Comparison	17
3.3	Pathway Profiling	18
<b>4</b>	<b>Discussion</b>	<b>18</b>
4.1	Ontology Overview of Top-Ranking Pathways	18
4.2	Ontology of Top-Ranking Genes	20
4.3	Oncogenic Targets of Top-Ranking miRNAs	21
4.4	Intra-pathway "Driver" Genes	21
<b>5</b>	<b>Conclusion</b>	<b>21</b>

# 1 Introduction

The use of computational tools to elucidate the mechanisms underlying the genetic, misregulatory aspect of cancer is intended to relieve the often tedious efforts made by wet-lab biologists to identify 'significant' genes and microRNAs by knock-out analysis. The goal of our pipeline is to allow researchers to screen cancer data sets for genes and miRNAs that are more likely to experimentally validate, leaving more time for investigation into molecular mechanisms less amenable to quantitative, bioinformatics analysis.

Most scripts developed for computational research in cancer biology are designed to predict clinicopathological features of tumors based on gene expression profiles. Such profiles are typically optimized to identify sets of genes whose expression is highly correlated with patient survival, tumor grade, chemotherapy sensitivity, etc.

*We postulate that the genes in expression profiles optimized for survival prediction in cancer patients are functionally implicated in the disease. Similarly, we propose that ranking genes by the correlation of their expression misregulation with differential patient survival will result in an ordering that reflects the extent of each gene's functional role in a specific cancer.*

Instead of following the canonical approach of identifying sets of genes whose expression can separate patients into two groups whose survivorship distributions are maximally 'different' (as measured by the log-rank statistic), our ranking algorithms take a gene-by-gene approach to measuring expression-survival correlation:

- MiRank-A follows a multi-step, non-traditional process that outputs a ranking metric  $T$  (for each gene/miRNA) that measures the correlation of differential expression with differential patient survival.
- MiRank-B is essentially MiRank-A, backwards. While MiRank-A orders patients by differential expression, then examines the resultant distribution of survival (across the ordered set of patients), MiRank-B first stratifies patients by differential survival then examines the resultant distribution of differential expression. An expression-survival correlation metric  $M$  follows from this analysis.
- MiRank-C is simply a univariate Cox regression (with expression misregulation values as covariates) that generates a set of regression coefficients,  $\beta$ , that can be used to rank genes/miRNAs by our expression-survival correlation scheme.

Our ranking scheme can also be extended to the world of microRNAs, short non-coding sequences of RNA that downregulate gene expression through RNA interference. In RNAi, one miRNA can target multiple genes. As such, we are able to examine the relationship between highly ranked miRNAs and highly ranked genes. We are especially interested in showing that the bipartite network of top-ranking genes and miRNAs is densely/sparsely connected, which reflects the efficacy of our ranking pipeline.

To justify our use of novel ranking methods, we compare the predictive power of the prognostic indices constructed by Yoshihara et. al. through 'traditional' expression profile-based methods to that of an index

generated by *our* pipeline outputs. We do so by performing a Cox regression on a rank-optimized, 260-gene prognostic index that is defined as follows.

$$I_k = \sum_{i=1}^{260} \beta_i \cdot X_{ik} \quad (1)$$

where  $X_{ik}$  is the expression misregulation metric of the  $i$ th ranked gene for the  $k$ th patient, and  $\beta_i$  is the corresponding regression coefficient. The regression delivers a hazard ratio that measures the correlation between patient survival and our prognostic index.

Though gene/miRNA ranking is sufficient for our specified goal of identifying genes and miRNAs of interest to researchers, we can do more. Genes do not act in isolation, but rather through regulatory networks of gene-product interactions. As such, rank data is more useful to biologists when placed in a pathway-centric context.

We accomplish this contextualization by (1) annotating KEGG Pathways gene-product wiring diagrams with color gradients that reflect the distribution of gene ranks within a pathway, (2) ranking pathways by their proportion of 'high' gene ranks, and (3) showing the enrichment of certain gene ontology (GO) terms in highly/poorly ranked functional groups of genes. Thus, we elucidate the functional roles played by highly ranked genes and miRNAs in tumorigenesis, which encapsulates excessive cell proliferation, migration, angiogenesis, etc.

The homebrew software packages that implement our analysis pipelines were written in Java, developed and tested on Mac OS X, and are freely available at <http://code.google.com/p/miranktool>. We have included sample inputs and outputs to illustrate the nature of our scripts.

## 2 Methods

### 2.1 Expression Misregulation Metric $X$

We propose the metric  $X$  to measure gene/miRNA expression misregulation.  $X$  is defined as follows.

$$X_i = \log_{10}(|f(\bar{C}_i, \bar{N}_i)|) \quad (2)$$


where  $C_i$  is the set of expression-values (across patients) for the  $i$ th gene/miRNA in *OV* (cancer sample set),  $\bar{C}_i$  is the mean of set  $C_i$ ,  $N_i$  is the set of expression-values (across patients) for the  $i$ th gene/miRNA in *NC* (normal control sample set), and  $\bar{N}_i$  is the mean of set  $N_i$ .  $f$  is defined as follows.

$$f(x, y) = \begin{cases} \frac{x}{y} & : x \geq y \\ -\frac{y}{x} & : x < y \\ 1 & : x = 0 \vee y = 0 \end{cases} \quad (3)$$


## 2.2 MiRank-A

### 2.2.1 Survival Spreads

We begin by ordering the patients in the input TCGA data set by their expression of gene/miRNA  $X$  (from least to greatest expression-value).



After ordering, we take iterative "slices," or groupings of patients, according to the following scheme.



We now generate a survival "spread" for each grouping. These "spreads" encapsulate the data necessary to calculate the log-rank statistic  $Z$  for each grouping. The log-rank statistic, also known as the Mantel-Cox test statistic, measures the similarity of the survival distributions of two patient groups (group 1 and group 2 in figure 1.2).

Generate survival "spread" for each grouping (example below for 'bottom 20 vs. top 160')

interval = 270  
 <=>  
 figures in corresponding row are recorded using data from patients for whom  
 $180 < \max(\text{days\_to\_death}, \text{days\_to\_last\_followup}) \leq 270$

num\_patients\_alive in succeeding row is calculated by subtracting the number of right-censored events (deaths and 'last followups') from num\_patients\_alive in preceding row

interval	num_patients_alive_group_1	num_deaths_group_1	num_patients_alive_group_2	num_deaths_group_2
90	160	7	20	1
180	150	0	19	0
270	142	5	18	0
360	131	5	18	0
450	124	3	17	2
540	119	5	15	0
630	114	5	15	2
720	105	4	13	0
810	97	1	12	0
900	91	5	12	0
990	85	4	11	0
1080	73	10	11	0
1170	61	3	10	1
1260	57	3	8	0
1350	53	2	8	0
1440	49	4	8	1
1530	44	3	7	0
1620	41	2	7	0
1710	39	3	7	2

After iterating this process across the set of genes/miRNAs  $\mathbf{X}$ , we are left with the set of survival spreads  $\mathbf{S}$ .

### 2.2.2 Log-Rank Matrices

Let us consider the survival spread  $S$ , which corresponds to a certain grouping of patients according to their expression of gene/miRNA  $X$ . With the data encapsulated by  $S$ , we may calculate  $Z$ , the log-rank statistic that measures the similarity between the survival distributions of groups 1 and 2.  $Z$  is defined as follows.

$$Z = \frac{\sum_{j=1}^J (O_{1j} - E_{1j})}{\sqrt{\sum_{j=1}^J V_j}} \quad (4)$$

where  $O_{nj}$  is the number of right-censored events occurring in group  $n$  at time  $j$ ,  $E_{nj}$  is the expected number of right-censored events occurring in group  $n$  at time  $j$ , and  $V_j$  is the variance of the  $O_j$  distribution (where  $O_j = O_{1j} + O_{2j}$ ).  $E_{nj}$  is defined as follows

$$E_{nj} = O_j \frac{N_{nj}}{N_j} \quad (5)$$

where  $N_{nj}$  is the number of patients in group  $n$  who have not yet died or been right-censored by time  $j$ , and  $N_j = N_{1j} + N_{2j}$ .  $V_j$  is defined as follows

$$V_j = \frac{O_j \left(\frac{N_{1j}}{N_j}\right) \left(1 - \frac{N_{1j}}{N_j}\right) (N_j - O_j)}{N_j - 1} \quad (6)$$

After calculating the log-rank statistic for each survival spread, we compile the  $Z$  values corresponding to the survival spreads associated with the gene/miRNA  $X$  into a matrix.

Generate log-rank statistic for each survival spread

interval	num_patients_alive_group_1	num_deaths_group_1	num_patients_alive_group_2	num_deaths_group_2
80	183	7	20	1
180	153	0	19	0
270	142	5	18	0
360	131	5	18	0
450	124	3	17	2
540	119	5	15	0
630	114	5	15	2
720	105	4	13	0
810	97	1	12	0
900	91	5	12	0
990	85	4	11	0
1080	75	10	11	0
1170	62	3	10	1
1260	57	3	8	0
1350	53	2	8	0
1440	49	4	8	1
1530	44	3	7	0
1620	41	2	7	0
1710	39	1	7	2

Z  
0.81838626

Compile log-rank matrix for each gene/miRNA

20	30	40	50	60	70	80	90	100	110	120	130	140	150	160	170	180	
20	0.7058711	0.013505391	0.00085287	0.3907844	0.7869004	0.01215197	0.047196	0.9914746	0.93270566	1.0000289	1.2308902	1.3560845	1.203171	1.2176819	1.2043535	1.2513123	1.24665945
30	0.8515273	0.1253488	0.23931058	0.59386945	0.612058	1.0548367	1.1361152	1.2613003	1.2427809	1.4148309	1.6475803	1.7413297	1.6799078	1.5978209	1.5803146	1.6404773	1.6447247
40	0.32115072	0.40312903	0.30153927	0.6324708	0.055179308	0.59954125	0.6080858	0.7774826	0.7250114	0.8808936	1.1207135	1.1895173	1.122602	1.0196102	0.9830824	1.0556073	1.0756023
50	0.12248924	0.6326223	0.5118952	0.21512632	0.22178322	0.2522456	0.2551282	0.3394752	0.44866627	0.6207953	0.8522171	0.9226929	0.85386044	0.7402751	0.68920173	0.74920724	0.8029005
60	0.038708370	0.7984884	0.7532112	0.43727467	0.42818272	0.18798155	0.15118859	0.3831882	0.2888357	0.42877322	0.4708882	0.74809913	0.6681288	0.54841783	0.47860389	0.58738156	0.61533068
70	0.1884041	0.9694945	0.9543821	0.64354956	0.5439019	0.05485153	0.06876569	0.12589915	0.06430536	0.18648688	0.43901187	0.50751216	0.41951567	0.28197587	0.20016684	0.24953325	
80	0.27307197	1.0677925	1.0905448	0.7840357	0.80043724	0.7992062	0.21902737	0.028224433	0.096402965	0.03097351	0.27258945	0.35794280	0.20947138	0.12503061	0.040066168		
90	0.20948712	1.1052761	1.0908056	0.80412533	0.81838626	0.71602518	0.22235751	0.016836872	0.05336213	0.046118494	0.27413803	0.36380075	0.2738012	0.13004068			
100	0.39549255	1.1610003	1.1647887	0.8739918	0.8986227	0.2472767	0.20820814	0.08877371	0.15217754	0.024894061	0.21098782	0.298975	0.20425862				
110	0.1015149	0.8024067	0.8649229	0.5475044	0.5493288	0.12647218	0.08482917	0.2041398	0.21045142	0.33695224	0.444239	0.7285765					
120	0.27523867	1.0988787	1.0964383	0.8008494	0.8109248	0.13412441	0.18949789	0.02292729	0.046720463	0.1099496	0.3128993						
130	0.17653283	1.0276157	1.0096127	0.6935019	0.70830125	0.020196008	0.0750771	0.14514058	0.08223082	0.2466379							
140	0.3849423	1.2522429	1.2545394	0.9530995	0.983005	0.29520676	0.37829560	0.19904768	0.23996094								
150	0.5777956	1.4946009	1.5051198	1.2205340	1.2649207	0.5730416	0.6783908	0.47649415									
160	0.5798941	1.4955804	1.5101428	1.2345333	1.272494	0.5818273	0.6847091										
170	0.6060244	1.5758966	1.5914304	1.2020433	1.2619845	0.6730803											
180	0.758961	1.700062	1.7281876	1.4624336	1.5109112												

Column labels correspond to the size of the "top" group.  
Row labels correspond to the size of the "bottom" group.

After iterating this process across the set of genes/miRNAs **X**, we are left with the set of log-rank matrices **M**.

### 2.2.3 Rank Spread

From our set of log-rank matrices **M**, we may generate the following "rank spread."

gene	max	grouping style (bottom;top)	min	grouping style (bottom;top)	mean	median	>1.96	>2.58
MPO	2.69414	40;550	0.0027628357	90;20	1.0409412	1.0260525	121	4
NOS2A	2.8279285	110;330	0.0029707423	30;410	1.4576112	1.5569885	353	15
NOX1	2.1204355	20;30	3.0830945E-4	110;50	0.7022139	0.60062206	3	0
NOX3	2.2322686	50;30	9.5873815E-4	400;190	0.90940815	0.96858096	11	0
NOX4	3.2543085	60;370	0.18381456	520;70	1.713567	1.7567335	663	133
NOX5	2.3433754	110;30	0.0014420918	440;70	0.8317974	0.831254	28	0
NR2F2	2.142266	110;480	0.0011862807	220;270	0.6040009	0.55641484	4	0
SOD1	2.0539865	30;140	1.1025997E-4	110;210	0.6685362	0.5379441	4	0
SOD2	1.7361692	420;90	4.99713E-4	20;150	0.62345415	0.60242546	0	0
SOD3	1.567376	500;90	6.001532E-4	160;350	0.44674462	0.37339982	0	0

where >1.96 represents the number of log-rank statistics in the matrix (corresponding to a certain gene/miRNA) whose values are greater than 1.96 (likewise for >2.58). Note that when  $Z > 1.96$ ,  $p < 0.05$ , and that when

$Z > 2.58, p < 0.01$ .

### 2.2.4 Expression-Survival Correlation Statistic $T$

We propose the metric  $T_i$  to measure the correlation of patient survival with the expression of the  $i$ th gene/miRNA.  $T_i$  is defined as follows.

$$T_i = \max(Z_i) \cdot \text{median}(Z_i) \quad (7)$$

where  $\max(Z_i)$  is the maximum log-rank statistic found in the log-rank matrix of the  $i$ th gene/miRNA, and  $\text{median}(Z_i)$  is the median of the log-rank statistics found in the log-rank matrix of the  $i$ th gene/miRNA.

## 2.3 MiRank-B

### 2.3.1 Patient Grouping

We begin by dividing patients into a series of 21 groups, according to the following scheme.

	subgroup A	subgroup B
group 1	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 90$ days ( $\sim 3$ months)
group 2	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 180$ days ( $\sim 6$ months)
group 3	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 365$ days ( $\sim 12$ months)
group 4	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 1095$ days ( $\sim 36$ months)
group 5	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 1825$ days ( $\sim 60$ months)
group 6	$t_{death} < 90$ days ( $\sim 3$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)
group 7	$t_{death} < 180$ days ( $\sim 6$ months)	$t_{death} > 180$ days ( $\sim 6$ months)
group 8	$t_{death} < 180$ days ( $\sim 6$ months)	$t_{death} > 365$ days ( $\sim 12$ months)
group 9	$t_{death} < 180$ days ( $\sim 6$ months)	$t_{death} > 1095$ days ( $\sim 36$ months)
group 10	$t_{death} < 180$ days ( $\sim 6$ months)	$t_{death} > 1825$ days ( $\sim 60$ months)
group 11	$t_{death} < 180$ days ( $\sim 6$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)
group 12	$t_{death} < 365$ days ( $\sim 12$ months)	$t_{death} > 365$ days ( $\sim 12$ months)
group 13	$t_{death} < 365$ days ( $\sim 12$ months)	$t_{death} > 1095$ days ( $\sim 36$ months)
group 14	$t_{death} < 365$ days ( $\sim 12$ months)	$t_{death} > 1825$ days ( $\sim 60$ months)
group 15	$t_{death} < 365$ days ( $\sim 12$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)
group 16	$t_{death} < 1095$ days ( $\sim 36$ months)	$t_{death} > 1095$ days ( $\sim 36$ months)
group 17	$t_{death} < 1095$ days ( $\sim 36$ months)	$t_{death} > 1825$ days ( $\sim 60$ months)
group 18	$t_{death} < 1095$ days ( $\sim 36$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)
group 19	$t_{death} < 1825$ days ( $\sim 60$ months)	$t_{death} > 1825$ days ( $\sim 60$ months)
group 20	$t_{death} < 1825$ days ( $\sim 60$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)
group 21	$t_{death} < 3650$ days ( $\sim 120$ months)	$t_{death} > 3650$ days ( $\sim 120$ months)

Figure 1.1.1

where  $t_{death}$  is equivalent to  $\max(\text{days\_to\_death}, \text{days\_to\_last\_followup})$ .



### 2.3.2 Expression and Correlation Statistics

For each group, we generate the following "expression statistics" across all genes/miRNAs:  $\min(\mathbf{X})$ ,  $\max(\mathbf{X})$ ,  $\text{median}(\mathbf{X})$ ,  $\text{mean}(\mathbf{X})$ , and  $\sigma(\mathbf{X})$ , where  $\mathbf{X}$  is the set of expression values for a given gene/miRNA. This information may later be used for verification/reference.

Additionally, for each group we generate the following "expression-survival correlation statistics" across all genes/miRNAs:  $O(A \cup B)$ ,  $O(B)$ ,  $O(A)$ ,  $f(B, A)$ ,  $t_e(B, A)$ ,  $p(t_e)$ ,  $t_u(B, A)$ , and  $p(t_u)$ , where  $O$  is the fraction of patients in the parameter-specified subgroup whose expression value falls within the range of expression values in the subgroup they are *not* contained in,  $f(B, A)$  is the fold change of expression values from subgroup  $A$  to subgroup  $B$ ,  $t_e$  is the student's t-test statistic testing the null hypothesis that the distribution of expression values in subgroup  $A$  and subgroup  $B$  are equal (assuming equal variance),  $p$  is the probability density function for the student's t-test distribution, and  $t_u$  is the student's t-test assuming *unequal* variance.  $O$  is defined as follows.

$$O(Z) = \frac{|I|}{|k|} \quad (8)$$

where  $I$  (subset of subgroup  $Z$ ) is the set of patients whose expression value falls within the range of expression values in the subgroup they are *not* contained in, and  $k$  is the set of patients in group  $k$ .  $f$  is defined as follows.

$$f(B, A) = \begin{cases} \frac{\bar{X}_B}{\bar{X}_A} & : \bar{X}_B \geq \bar{X}_A \\ -\frac{\bar{X}_A}{\bar{X}_B} & : \bar{X}_B < \bar{X}_A \end{cases} \quad (9)$$

where  $\bar{X}_A$  is the mean expression-value in subgroup  $A$  (likewise for  $\bar{X}_B$  and subgroup  $B$ ).  $t_e$  is defined as follows.

$$t_e(B, A) = \frac{\bar{X}_B - \bar{X}_A}{\sqrt{\frac{(|B|-1)\text{Var}(X_B) + (|A|-1)\text{Var}(X_A)}{|B|+|A|-2} \sqrt{\frac{1}{|B|} + \frac{1}{|A|}}}} \quad (10)$$

$t_u$  is defined as follows.

$$t_u(B, A) = \frac{\bar{X}_B - \bar{X}_A}{\sqrt{\frac{\text{Var}(X_B)}{|B|} + \frac{\text{Var}(X_A)}{|A|}}} \quad (11)$$

$p$  is defined as follows.

$$p(t) = \frac{\Gamma(\frac{\nu+1}{2})}{\sqrt{\nu\pi}\Gamma(\frac{\nu}{2})} \left(1 + \frac{t^2}{\nu}\right)^{-\frac{\nu+1}{2}} \quad (12)$$

where  $\nu$  is the degrees of freedom of  $t$ , and  $\Gamma(n)$  is the Gamma function (Lanczos approximation of  $(n-1)!$ ).  $\nu$  is defined as follows.

$$\nu(B, A) = \frac{\left(\frac{\text{Var}(X_B)}{|B|} + \frac{\text{Var}(X_A)}{|A|}\right)^2}{\frac{(\frac{\text{Var}(X_B)}{|B|})^2}{|B|-1} + \frac{(\frac{\text{Var}(X_A)}{|A|})^2}{|A|-1}} \quad (13)$$





days\_to\_last\_follow\_up for each patient in the TCGA data set the input TCGA data set, one can plot a Kaplan-Meier step function that approximates  $S(t)$  within specified intervals. Specifically, the KM curve is a plot of  $\hat{S}(t)$ , the maximum likelihood estimate of  $S(t)$ , over time.  $\hat{S}(t)$  is defined as

$$\hat{S}(t) = \prod_{t_i < t} \frac{n_i - d_i}{n_i} \quad (15)$$

where  $n_i$  is the number of survivors less the number of right-censored losses that occur in the input TCGA data set at time  $t_i$ , and  $d_i$  is the number of deaths that occur in the input TCGA data set at time  $t_i$ . Thus,  $S(t)$  is associated with the clinical information encapsulated by the input TCGA data set.

The hazard function  $\lambda(t) = -\frac{S'(t)}{S(t)}$  describes the instantaneous density of events (deaths and right-censored losses) at time  $t$ . The cumulative hazard function  $\Lambda(t) = \int_0^t \lambda(u) du = -\ln(S(t))$  describes the accumulated hazard from time 0 to time  $t$ . Thus,  $\Lambda(t)$  is associated with  $S(t)$ .

### 2.4.2 Cox Proportional-Hazards Model

The Cox Proportional-Hazards Model allows us to relate certain covariates, or explanatory variables, to the cumulative hazard function through the following parameterization

$$\Lambda(t|\mathbf{X})_k = \Lambda_0(t)_k e^{\beta_0 X_{0,k} + \beta_1 X_{1,k} + \beta_2 X_{2,k} + \dots + \beta_n X_{n,k}} \quad (16)$$

where  $\Lambda_0(t)_k$  is the baseline hazard function for the  $k$ th patient,  $\mathbf{X}_k$  is the vector of covariates for the  $k$ th patient, and  $\beta$  is the set of regression coefficients.  $\mathbf{X}_k$  is defined as the vector of expression covariates, where  $X_{ik}$  is the expression misregulation metric of the  $i$ th gene/miRNA in the  $k$ th patient.

Under this relation, covariate  $X_{ik}$  has a multiplicative effect proportional to  $\beta_i$  on hazard. Thus, gene/miRNA expression misregulation is associated with patient survival.

### 2.4.3 Cox Regression

Our goal is to rank genes/miRNAs by the correlation of their expression misregulation with differential patient survival. We accomplish this by estimating the values of the regression coefficients  $\beta$  from equation (16), which can then be used to compare the hazard ratios of genes/miRNAs. First, let us define the following functions.

The partial likelihood function describes the probability of a parameter in an equation like (16) having a certain value given a set of observed data. Partial likelihood is defined as follows

$$L_n(\beta_n) = \prod_t \left( \frac{e^{X_n \beta_n}}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)} \right)^{D(t)} \quad (17)$$

where  $t$  is a discrete unit of time (at which at least one event occurs),  $\mathbf{R}$  is the set of patients still at risk at time  $t$ ,  $X_{nk}$  is the expression misregulation value for the  $n$ th gene/miRNA of the  $k$ th patient,  $X_n$  is the sum of the expression misregulation values of the patients dying at time  $t$ ,  $D_k(t)$  is the probability of the  $k$ th

patient's death at time  $t$ , and  $D(t)$  is the number of deaths that occur at time  $t$ .

The log partial likelihood, which produces more computationally 'convenient' probability figures than the partial likelihood, is defined as follows

$$l_n(\beta_n) = \ln(L(\beta_n)) = \sum_t \left[ D(t) \left( X_n \beta_n - \ln \left( \sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t) \right) \right) \right] \quad (18)$$

Our goal is to find  $\hat{\beta}$ , the set of maximum partial likelihood estimates (MPLES) for  $\beta$ . To do so, we must find the  $\beta_n$ -values that maximize their log partial likelihood functions  $l_n(\beta_n)$ .

We maximize  $l_n(\beta_n)$  by approximating the roots of its first derivative using Newton's method. This gives us  $\beta_n$ -values that correspond to the extreme points of  $l_n$ . The  $\beta_n$ -value that corresponds to the extreme point with the greatest  $l_n$  value will be our MPLE.

The partial score function is defined as follows.

$$l'_n(\beta_n) = \sum_t \left[ D(t) \left( X_n - \frac{\sum_{k \in \mathbf{R}} X_{nk} e^{X_{nk} \beta_n} D_k(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)} \right) \right] \quad (19)$$

The first derivative of the partial score function (second derivative of  $l_n(\beta_n)$ ) is defined as follows.

$$l''_n(\beta_n) = - \sum_t D(t) \left[ \frac{\sum_{k \in \mathbf{R}} X_{nk}^2 e^{X_{nk} \beta_n} D_k(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)} - \left( \frac{\sum_{k \in \mathbf{R}} X_{nk} e^{X_{nk} \beta_n} D_k(t)}{\sum_{k \in \mathbf{R}} e^{X_{nk} \beta_n} D_k(t)} \right)^2 \right] \quad (20)$$

Newton's method, also called the Newton-Raphson algorithm, for approximating the zeroes of a univariate function  $f(x)$  is described by the following recursive relation

$$x_{n+1} = x_n - \frac{f(x_n)}{f'(x_n)} \quad (21)$$

Applying Newton's method to the approximation of the roots of the partial score function, we find that

$$\beta_{n,k+1} = \beta_{n,k} - \frac{l'(\beta_{n,k})}{l''(\beta_{n,k})} \quad (22)$$

where  $\beta_{n,k}$  is the  $k$ th iteration on the value  $\beta_n$ . After applying this recursive relation to each value in  $\beta$ , we are left with our set of MPLEs  $\hat{\beta}$ .

#### 2.4.4 Gradient Descent with Modification

Although the convergence rate of Newton's method is fairly high, reducing the computational complexity of MiRank-C, the log partial likelihood function does not conform to *all* the preconditions of the Newton-Raphson algorithm. Because the partial score function is discontinuous, Newton's method can sometimes encounter an  $x$ -value outside the likelihood function's continuous interval, causing the recursive relation to 'diverge' permanently. For this reason, we must modify our approach to approximating the zero of the partial score function.

We propose a 'gradient descent with modification' approach to approximating the zero of the partial score

function for  $\beta_n$  values that 'escape' the likelihood function's interval of continuity during an iteration of Newton's method. The algorithm is as follows on the next page.

## 2.5 Pathway Profiling

### 2.5.1 Consolidated Rank $\alpha$

To simplify our enrichment analyses, we propose the following 'consolidated' rank  $\alpha$ .

$$\alpha_i = \frac{Z(\beta_i) + Z(M_i) + Z(T_i) + Z(X_i)}{4} \quad (23)$$

where  $Z$  is the normalization function defined as follows.

$$Z(Y_i) = \frac{Y_i - \bar{Y}}{\sigma(\mathbf{Y})} \quad (24)$$

where  $\bar{Y}$  is the mean of set  $\mathbf{Y}$ , and  $\sigma(\mathbf{Y})$  is the standard deviation of set  $\mathbf{Y}$ .

### 2.5.2 KEGG Pathway Enrichment


With our set of ranks  $\alpha$ , we can now take gene classes defined in KEGG Pathways (i.e. Ubiquitin-mediated Proteolysis Pathway, p53 Signaling Pathway, etc.) and calculate Fisher's one-sided exact test statistic  $\tau$  for each. This figure ranks each pathway by the proportion of occurrences of "high" ranks in its gene/miRNA class against the occurrences of "high" ranks in *all* genes being considered.  $\tau$  is defined as follows.

$$\tau_i = \frac{\frac{|G_P|}{|P_i|}}{\frac{|G_X|}{|\mathbf{X}|}} = \frac{|G_P|}{|G_X|} \cdot \frac{|\mathbf{X}|}{|P_i|} \quad (25)$$

where  $\mathbf{P}$  is the set of genes implicated in the  $i$ th pathway,  $\mathbf{X}$  is the vector of genes/miRNAs under consideration,  $G_P$  is the subset of  $\mathbf{P}$  for which  $\alpha_n \geq \bar{\alpha}$ , and  $G_X$  is the subset of  $\mathbf{X}$  for which  $\alpha_n \geq \bar{\alpha}$ .

$\tau_i$  now represents the enrichment of the  $i$ th pathway with highly ranked genes.

# Gradient Descent with Modification



### 2.5.3 Clustering

We cluster using a self-organizing map (SOM), a method that produces clusters that are more "stable" but less "compact" than those produced by k-means partitioning, partitioning around medoids, etc. The algorithm is as follows.

1. Let  $\mathbf{x}_i : \{\beta_i, M_i, T_i, X_i\}$  be the vector associated with the  $i$ th gene/miRNA.
2. Randomly choose a sample vector  $\mathbf{x}$  from the input data set.
3. Find the gene/miRNA whose vector minimizes the following

$$\|\mathbf{x} - \mathbf{m}_b\| = \min_i \{\|\mathbf{x} - \mathbf{m}_i\|\} \quad (26)$$

where  $\mathbf{m}_i$  is the vector associated with the  $i$ th gene,  $b$  denotes the best-matching unit (BMU), and  $\|\mathbf{a} - \mathbf{b}\|$  represents the Euclidean distance between  $\mathbf{a}$  and  $\mathbf{b}$ .

4. Update gene/miRNA vectors (excepting the BMU) according to the following rule.

$$\mathbf{m}_i(t+1) = \mathbf{m}_i(t) + \alpha(t)h_{bi}(t)[\mathbf{x} - \mathbf{m}_i(t)] \quad (27)$$

where  $t$  is time,  $\alpha$  is the learning rate, and  $h_{bi}$  is the neighborhood kernel centered on the BMU.  $\alpha(t)$  is defined as follows.

$$\alpha(t) = \frac{1}{1 + \ln(t)} \quad (28)$$

$h_{bi}$  is defined as follows.

$$h_{bi}(t) = \exp\left(-\frac{\|\mathbf{m}_b - \mathbf{m}_i\|}{2\sigma^2(t)}\right) \quad (29)$$

where  $\sigma(t)$  is defined as follows.

$$\sigma(t) = \frac{1}{1 + \ln(t)} \quad (30)$$

5. Repeat steps 2-4 until  $\alpha < 0.25$

### 2.5.4 Partitioning

After clustering with an SOM, we apply hierarchical agglomerative clustering to the resultant set of vectors, thus assigning each gene/miRNA to a discrete partition in a series of "levels." The algorithm is as follows.

1. Place each sample vector from the input data set into its own singleton partition.
2. Merge the two closest partitions. The distance between a partition  $A$  and partition  $B$  is defined as follows.

$$d(A, B) = \frac{1}{|A||B|} \sum_{i \in A} \sum_{j \in B} \|i - j\| \quad (31)$$

3. Add the current set of partitions to level  $k$ , where  $k$  is the distance between the two closest partitions from step 2.
4. Repeat steps 2 and 3 until all the data are merged into a single partition.

After judicious analysis of pipeline outputs, one may select a set of partitions with an 'appropriate' magnitude of separation.



### 2.5.5 GO Term Enrichment

After delineating partitions, we generate a spread of GO terms associated with the genes in each partition. Additionally, we show the relative frequencies of occurrences of GO terms within each partition. Gene:Term associations were found using data from <ftp://ftp.ebi.ac.uk/pub/databases/GO/goa/HUMAN/>. Term descriptions were also web-scraped from <http://www.ebi.ac.uk/QuickGO>.

## 3 Results

### 3.1 Gene/miRNA Ranking

gene	Consolidated Rank (Alpha)	miR	Consolidated Rank (Alpha)
TCF7	6.4270535	hsa-miR-34c-3p	5.2762966
RPS6KA2	2.3743002	hsa-miR-139-5p	2.2229412
SOCS2	1.99857	hsa-miR-133a	2.1366444
TNFRSF4	1.9086596	hsa-miR-34c-5p	2.0398793
LAMB2	1.7359532	hsa-miR-155	1.4723357
CCND2	1.6566322	hsa-miR-515-5p	1.4626533
FZD5	1.5173668	hsa-miR-486-5p	1.3781605
CHP	1.4788748	hsa-miR-449a	1.3206564
CCR7	1.418112	hsa-miR-938	1.2998003
RALA	1.3220334	hsa-miR-211	1.2449175
CCL3	1.2700129	hsa-miR-604	1.2163122
TNFRSF10B	1.2098999	hsa-miR-890	1.1966283
CXCL9	1.203721	hsa-miR-455-5p	1.1835667
DTX3L	1.1925004	hsa-miR-34b	1.1783645
FZD10	1.1643226	hsa-miR-142-3p	1.1649697
CD27	1.1547524	hsa-miR-146a	1.123212
MMP9	1.1547232	hsa-miR-504	1.1161133
CHP2	1.1415317	hsa-miR-519d	1.1075377
IL5RA	1.1056126	hsa-miR-96	1.0646632
TBL1XR1	1.0584645	hsa-miR-632	0.9008667

Top 20 Genes/miRNAs, by Rank

### 3.2 Prognostic Index Performance Comparison

The 260-gene prognostic index constructed from the outputs of our ranking pipeline achieved a hazard ratio of 1.15 (a 1 unit increase in a patient's prognostic index corresponds to a 1.15x increase in a patient's 'hazard', or risk of death). Yoshihara et. al. reported an HR of 1.62 for their genetic profile-based survival index (applied to Tothill's data set of serous ovarian cancer patients).

### 3.3 Pathway Profiling

pathway	kegg_id	tau	g_p	P	g_x	X
Wnt signaling pathway - Homo sapiens (human)	4310	1.0864226	68	146	463	1080
Notch signaling pathway - Homo sapiens (human)	4330	1.0849365	20	43	463	1080
Pathways in cancer - Homo sapiens (human)	5200	1.0835366	144	310	463	1080
VEGF signaling pathway - Homo sapiens (human)	4370	1.0513186	32	71	463	1080
MAPK signaling pathway - Homo sapiens (human)	4010	1.048772	116	258	463	1080
Apoptosis - Homo sapiens (human)	4210	1.036717	36	81	463	1080
Focal adhesion - Homo sapiens (human)	4510	1.0312606	84	190	463	1080
TGF-beta signaling pathway - Homo sapiens (human)	4350	1.0299851	34	77	463	1080
Cytokine-cytokine receptor interaction - Homo sapiens (human)	4060	1.0175186	106	243	463	1080
Hedgehog signaling pathway - Homo sapiens (human)	4340	0.9996915	24	56	463	1080
Jak-STAT signaling pathway - Homo sapiens (human)	4630	0.9950309	61	143	463	1080
Cell cycle - Homo sapiens (human)	4110	0.9908446	48	113	463	1080
p53 signaling pathway - Homo sapiens (human)	4115	0.8412704	22	61	463	1080


Pathway Enrichment

The following gene-product wiring diagrams were taken from the KEGG Pathways database and annotated (coloured) by our scripts.

## 4 Discussion

### 4.1 Ontology Overview of Top-Ranking Pathways

- The Wnt signaling pathway plays a significant role in cell-fate specification and progenitor-cell proliferation, which is significantly upregulated in cancerous germ line cells that give rise to (ovarian) epithelial cells.
- Activation of the VEGF signaling pathway leads to the upregulation of genes involved in mediating the proliferation and migration of endothelial cells and promoting their survival and vascular permeability, a key attribute of tumorigenic cells.
- The MAPK signaling pathway regulates critical cellular functions like proliferation, differentiation, and migration: functions whose misregulation is associated with cancer.
- The Notch signaling pathway encodes the processes necessary for intercellular signaling, which is necessary for tumorigenesis and cell migration (metastasis).
- Apoptosis, or programmed cell death, is often suppressed once a cell undergoes carcinogenesis.



A gradient (passing through dark gray for values near the mean) separates low-ranking genes, in bright green, from high-ranking genes, in bright red.



### 4.3 Oncogenic Targets of Top-Ranking miRNAs

hsa-miR-34c-3p										
hsa-miR-139-5p	JUN (26)	FOS (138)	SOCS2 (4)	ITGA3 (27)	RAP1B (96)					
hsa-miR-133a	PPP2CB (54)	TNFRSF10B (13)	EGFR (25)	PPP2R5E (124)	SPI1 (66)	ID4 (41)	TGFBRI (148)	CHP (9)		
hsa-miR-34c-5p	IL6R (106)									
hsa-miR-155	SP1 (66)	FOS (138)	KRAS (69)	FZD5 (8)	CBL (105)	YWHAZ (87)	SPI1 (74)	SOS1 (86)	RAP1B (96)	ARRB2 (47)
hsa-miR-515-5p	BMP8B (56)	PIK3CG (145)	RAP1B (96)	GADD45B (24)						
hsa-miR-486-5p										
hsa-miR-449a	NUMBL (103)	TBL1XR1 (21)								
hsa-miR-938	YWHAZ (87)	SPRED2 (79)	E2F3 (94)							
hsa-miR-211	VHL (107)									
hsa-miR-604										
hsa-miR-890	CHP (9)									
hsa-miR-455-5p	SOCS3 (114)	NLK (92)	FZD5 (8)	TBL1XR1 (21)						
hsa-miR-34b	ITGA2 (82)	TGFA (29)								
hsa-miR-142-3p	TGFBRI (148)	PPP3CA (93)								
hsa-miR-146a										
hsa-miR-504	RAP1B (96)									
hsa-miR-519d										
hsa-miR-96	KRAS (69)	BCR (113)	PPP3CA (93)	NF1 (77)	SOS1 (86)	CCND2 (7)	FGF9 (99)			
hsa-miR-632	RAPGEF1 (112)	NTRK2 (127)	TRAF4 (147)							

miRNA: Gene Targets (Position on list, sorted by rank)

### 4.4 Intra-pathway "Driver" Genes

Functional groups of genes mentioned below are highly ranked within their respective pathways (and are coloured red in their annotated KEGG diagrams).

*Pathways in Cancer (KEGG 05200)*: (1) upregulation of TCF leads to evasion of apoptosis, programmed cell death; (2) upregulation of Wnt leads to excessive cell proliferation; (3) upregulation of VEGF, Jun and Fos leads to sustained angiogenesis, which provides nourishment for the growing tumor.

*Apoptosis (KEGG 04210)*: (1) downregulation of Cn leads to downregulation of one of the Ca<sup>2+</sup>-induced Cell Death Pathways involved in apoptosis; (2) downregulation of CASP8 leads to the downregulation of dna fragmentation and cell degradation.

*MAPK Signaling Pathway (KEGG 04010)*: (1) upregulation of Fos leads to excessive cell proliferation and differentiation (in germ lines); (2) upregulation of NFkB leads to cell proliferation, inflammation and anti-apoptosis.

## 5 Conclusion

The outputs of our analysis pipeline support our hypothesis that the expression-survival correlation scheme described in Section 2 can be used to rank and identify genes/miRNAs that play critical roles in ovarian carcinoma.

- Several top-ranking functional groups of genes (Wnt, VEGF, Jun, Fos, etc.) are already known to be involved in tumorigenesis.
- Several miRNAs in our top-20 set (sorted by rank) have targets in the top two quartiles of genes.
- The misregulation of highly-ranked genes in enriched pathways drives excessive cell proliferation, migration, angiogenesis, etc., which are characteristic of ovarian carcinoma.

Researchers now have at their disposal a series of open-source scripts that can be used to screen TCGA and KEGG data sets for genes/miRNAs and pathways of 'interest' in a given cancer.

The hazard ratio of our prognostic index was slightly below those reported by Yoshihara et. al. As such, to improve our experimental procedure, we could closely examine our ranking scheme and perhaps expand its scope. As described in Section 2, our pipeline takes only expression data and clinical information as inputs. Integrating other genomic characterizations of ovarian cancer provided by TCGA, like copy-number aberrations and dna methylation irregularities, into MiRank-A/B/C could improve the performance of our prognostic index, and thus, the selectiveness of our gene/miRNA ranking.

In examining the outputs of CBioKconnect (<http://sourceforge.net/projects/cbiokconnect/>), a data visualization tool we developed last summer, we found that several genes (including p53, a tumor suppressor that is typically downregulated in cancer) are heavily mutated in ovarian carcinoma, but seem to have 'normal' expression levels according to TCGA and CBioPortal data. This is most likely because the oligonucleotide probes in most expression microarrays are not designed to measure the up/down-regulation of genes that occurs due to mutation.

This masking of the 'true' expression levels of genes like p53 highlights a deficiency in our analysis pipeline: a reliance on 'incomplete' expression data from TCGA. If we were to calculate the effective expression levels of genes/miRNAs rather than rely solely on TCGA microarray data, I'm sure we would find many more of them to be misregulated (and thus, more highly ranked).

The results of our pathway-centric profiling of TCGA data sets lead us to wonder how cancer has evolved to target such a diverse range of genes and miRNAs, especially those that regulate critical cellular functions. If protein-protein interaction networks are as robust as most quantitative biology studies claim, how is it that a single disease can misregulate several pathways to such an extent that a cell becomes cancerous? Examining the topology of the network of genes/miRNAs targeted by various cancers and showing that it reflects an optimal selection of network nodes to misregulate (in order to accomplish excessive cell proliferation, migration, etc.) would highlight key elements of cancer's "network of misregulation" and allow researchers to design drugs that target genes/miRNAs that act as "drivers" of misregulated cellular activity.

## References

- [1] *SOM Toolbox for Matlab 5*.
- [2] *Fundamentals of Artificial Neural Networks*. MIT Press, 1995.
- [3] *An R and S-PLUS Companion to Applied Regression*, chapter Appendix: Cox Proportional-Hazards Regression for Survival Data. Sage Publications, Inc, 2002.
- [4] David M. Blei. Hierarchical clustering. Lecture Slides, February 2008.
- [5] Elizabeth R. Brown. Cox proportional hazards models. Lecture Slides, March 2004.
- [6] Gengxin Chen, Saied A Jaradat, Nila Banerjee, Tetsuya S Tanaka, Minoru S H Ko, and Michael Q Zhang. Evaluation and comparison of clustering algorithms in analyzing es cell gene expression data. *Statistica Sinica*, 12(1):241262, 2002.
- [7] Anne P. G Crijns, Rudolf S. N Fehrmann, Steven de Jong, Frans Gerbens, Gert Jan Meersma, Harry G Klip, Harry Hollema, Robert M. W Hofstra, Gerard J. te Meerman, Elisabeth G. E de Vries, and Ate G. J van der Zee. Survival-related profile, pathways, and transcription factors in ovarian cancer. *PLoS Med*, 6(2):e1000024, 02 2009.
- [8] R. K. Gaire, J. Bailey, J. Bearfoot, I. G. Campbell, P. J. Stuckey, and I. Haviv. MIRAGAA—a methodology for finding coordinated effects of microRNA expression changes and genome aberrations in cancer. *Bioinformatics*, 26:161–167, Jan 2010.
- [9] H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, and M. D. Johnson. Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. *Proc. Natl. Acad. Sci. U.S.A.*, 107:2183–2188, Feb 2010.
- [10] Panagiotis A Konstantinopoulos, Dimitrios Spentzos, and Stephen A Cannistra. Gene-expression profiling in epithelial ovarian cancer. *Nat Clin Prac Oncol*, 5(10):577–587, 10 2008.
- [11] Professor Pier Luca Lanzi. Clustering: Partitioning methods (machine learning and data mining). Lecture Slides.
- [12] Parminder K. Mankoo, Ronglai Shen, Nikolaus Schultz, Douglas A. Levine, and Chris Sander. Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles. *PLoS ONE*, 6(11):e24709, 11 2011.
- [13] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*, 474:609–615, Jun 2011.
- [14] Sujaya Srinivasan, Irene Rosita Pia Patric, and Kumaravel Somasundaram. A ten-microrna expression signature predicts survival in glioblastoma. *PLoS ONE*, 6(3):e17438, 03 2011.
- [15] Xuan Bich Trinh, Wiebren A. A. Tjalma, Luc Y. Dirix, Peter B. Vermeulen, Dieter J. Peeters, Dimcho Bachvarov, Marie Plante, Els M. Berns, Jozien Helleman, Steven J. Van Laere, and Peter A. van Dam. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. *PLoS ONE*, 6(7):e22469, 07 2011.

- [16] Marc J. van de Vijver, Yudong D. He, Laura J. van 't Veer, Hongyue Dai, Augustinus A.M. Hart, Dorien W. Voskuil, George J. Schreiber, Johannes L. Peterse, Chris Roberts, Matthew J. Marton, Mark Parrish, Douwe Atsma, Anke Witteveen, Annuska Glas, Leonie Delahaye, Tony van der Velde, Harry Bartelink, Sjoerd Rodenhuis, Emiel T. Rutgers, Stephen H. Friend, and Ren Bernards. A gene-expression signature as a predictor of survival in breast cancer. *New England Journal of Medicine*, 347(25):1999–2009, 2002.
- [17] Juha Vesanto and Esa Alhoniemi. Clustering of the self-organizing map. *IEEE Transactions on Neural Networks*, 2000.
- [18] Kosuke Yoshihara, Atsushi Tajima, Tetsuro Yahata, Shoji Kodama, Hiroyuki Fujiwara, Mitsuaki Suzuki, Yoshitaka Onishi, Masayuki Hatae, Kazunobu Sueyoshi, Hisaya Fujiwara, Yoshiki Kudo, Kohei Kotera, Hideaki Masuzaki, Hironori Tashiro, Hidetaka Katabuchi, Ituro Inoue, and Kenichi Tanaka. Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. *PLoS ONE*, 5(3):e9615, 03 2010.
- [19] J. X. Yu, A. M. Sieuwerts, Y. Zhang, J. W. Martens, M. Smid, J. G. Klijn, Y. Wang, and J. A. Foekens. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. *BMC Cancer*, 7:182, 2007.
- [20] Dr. Daowen Zhang. Analysis of survival data. Lecture Notes, Spring 2005.